The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

2020 ASCO Update on mCRC: Does T-DXd Have Potential in HER2+ Disease Refractory to Standard Therapies?

28 views
September 9, 2020
0 Comments
Login to view comments. Click here to Login
2020 ASCO Highlights